 Stephen Keysar
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 17 | 2023 | 427 | 3.050 |
Why?
| | Neoplastic Stem Cells | 9 | 2022 | 329 | 2.210 |
Why?
| | Carcinoma, Squamous Cell | 12 | 2022 | 577 | 1.880 |
Why?
| | Xenograft Model Antitumor Assays | 14 | 2020 | 698 | 0.840 |
Why?
| | Biomarkers, Tumor | 5 | 2021 | 1040 | 0.790 |
Why?
| | SOXB1 Transcription Factors | 3 | 2021 | 60 | 0.760 |
Why?
| | CD59 Antigens | 4 | 2009 | 21 | 0.700 |
Why?
| | ErbB Receptors | 5 | 2022 | 554 | 0.680 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 42 | 0.680 |
Why?
| | Cetuximab | 5 | 2021 | 90 | 0.640 |
Why?
| | Flow Cytometry | 5 | 2010 | 1083 | 0.640 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2013 | 663 | 0.630 |
Why?
| | Peptides, Cyclic | 1 | 2020 | 253 | 0.600 |
Why?
| | Phosphatidylinositol 3-Kinase | 2 | 2022 | 26 | 0.600 |
Why?
| | Salivary Gland Neoplasms | 1 | 2018 | 31 | 0.590 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2019 | 1141 | 0.590 |
Why?
| | Chromosomes, Human, Pair 11 | 5 | 2010 | 58 | 0.580 |
Why?
| | Hedgehog Proteins | 3 | 2015 | 172 | 0.530 |
Why?
| | Cell Line, Tumor | 13 | 2022 | 2710 | 0.530 |
Why?
| | Hyaluronan Receptors | 5 | 2020 | 90 | 0.490 |
Why?
| | Veratrum Alkaloids | 2 | 2014 | 17 | 0.460 |
Why?
| | Mutagenicity Tests | 2 | 2009 | 9 | 0.410 |
Why?
| | Mice | 20 | 2023 | 14859 | 0.410 |
Why?
| | Mice, Nude | 8 | 2019 | 630 | 0.400 |
Why?
| | DNA Mutational Analysis | 2 | 2009 | 372 | 0.360 |
Why?
| | Animals | 26 | 2023 | 31692 | 0.360 |
Why?
| | RNA, Messenger | 2 | 2016 | 2552 | 0.340 |
Why?
| | Cell Proliferation | 9 | 2019 | 2186 | 0.340 |
Why?
| | Mutation | 5 | 2018 | 3344 | 0.320 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 1355 | 0.320 |
Why?
| | Point Mutation | 1 | 2009 | 216 | 0.310 |
Why?
| | Tumor Microenvironment | 4 | 2022 | 430 | 0.310 |
Why?
| | Antineoplastic Agents | 5 | 2016 | 1879 | 0.300 |
Why?
| | Smad4 Protein | 2 | 2019 | 34 | 0.270 |
Why?
| | Tumor Cells, Cultured | 5 | 2019 | 849 | 0.250 |
Why?
| | Oxygen | 1 | 2010 | 854 | 0.250 |
Why?
| | Disease Models, Animal | 6 | 2020 | 3531 | 0.240 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2017 | 179 | 0.230 |
Why?
| | Receptor, Notch1 | 2 | 2015 | 59 | 0.230 |
Why?
| | Hematopoietic Stem Cells | 2 | 2018 | 343 | 0.220 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1629 | 0.220 |
Why?
| | Immunophenotyping | 3 | 2019 | 273 | 0.220 |
Why?
| | Sulfones | 2 | 2014 | 97 | 0.210 |
Why?
| | Glycine | 2 | 2014 | 152 | 0.210 |
Why?
| | Signal Transduction | 8 | 2017 | 4509 | 0.210 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2020 | 858 | 0.210 |
Why?
| | Humans | 33 | 2023 | 114599 | 0.210 |
Why?
| | CHO Cells | 4 | 2010 | 138 | 0.200 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 139 | 0.200 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2022 | 329 | 0.200 |
Why?
| | Cricetinae | 4 | 2010 | 253 | 0.200 |
Why?
| | Papillomaviridae | 3 | 2019 | 101 | 0.200 |
Why?
| | Caveolin 1 | 1 | 2021 | 20 | 0.190 |
Why?
| | Cricetulus | 3 | 2010 | 97 | 0.180 |
Why?
| | Ethyl Methanesulfonate | 3 | 2009 | 3 | 0.180 |
Why?
| | DNA Repair | 2 | 2020 | 184 | 0.180 |
Why?
| | Neoplasms | 2 | 2014 | 2097 | 0.180 |
Why?
| | Precancerous Conditions | 1 | 2022 | 158 | 0.180 |
Why?
| | Heterografts | 2 | 2019 | 117 | 0.180 |
Why?
| | Antigens, CD | 2 | 2016 | 442 | 0.170 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.170 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2020 | 127 | 0.170 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 152 | 0.170 |
Why?
| | Protein Kinase Inhibitors | 2 | 2015 | 785 | 0.170 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 244 | 0.170 |
Why?
| | Stem Cell Niche | 1 | 2019 | 42 | 0.160 |
Why?
| | Mouth Neoplasms | 1 | 2019 | 70 | 0.160 |
Why?
| | Carcinogenesis | 2 | 2018 | 177 | 0.160 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 48 | 0.160 |
Why?
| | Neoplasm Transplantation | 2 | 2016 | 228 | 0.160 |
Why?
| | Radiotherapy | 1 | 2019 | 176 | 0.160 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 188 | 0.150 |
Why?
| | Chromosome Aberrations | 1 | 2019 | 135 | 0.150 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2018 | 37 | 0.150 |
Why?
| | Papillomavirus Infections | 2 | 2019 | 261 | 0.150 |
Why?
| | Mutagens | 2 | 2009 | 17 | 0.150 |
Why?
| | Radiation Tolerance | 2 | 2016 | 92 | 0.150 |
Why?
| | DNA Damage | 1 | 2020 | 351 | 0.140 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2016 | 308 | 0.140 |
Why?
| | Gene Deletion | 1 | 2019 | 356 | 0.140 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 146 | 0.140 |
Why?
| | Cell Communication | 1 | 2018 | 279 | 0.140 |
Why?
| | Cell Cycle | 1 | 2020 | 542 | 0.140 |
Why?
| | Receptor, EphB4 | 1 | 2016 | 23 | 0.140 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 386 | 0.140 |
Why?
| | Immunotherapy | 1 | 2020 | 474 | 0.140 |
Why?
| | Corynebacterium | 1 | 2017 | 35 | 0.140 |
Why?
| | Retinal Dehydrogenase | 1 | 2016 | 33 | 0.140 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 358 | 0.140 |
Why?
| | Corynebacterium Infections | 1 | 2017 | 31 | 0.140 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 79 | 0.130 |
Why?
| | Neoplasms, Experimental | 1 | 2017 | 151 | 0.130 |
Why?
| | Spheroids, Cellular | 1 | 2016 | 56 | 0.130 |
Why?
| | Proto-Oncogene Proteins | 3 | 2014 | 608 | 0.130 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2016 | 102 | 0.130 |
Why?
| | Cadherins | 1 | 2016 | 175 | 0.120 |
Why?
| | Oncogene Proteins | 1 | 2015 | 53 | 0.120 |
Why?
| | Recurrence | 1 | 2018 | 935 | 0.120 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2015 | 52 | 0.120 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2015 | 31 | 0.120 |
Why?
| | Gene Dosage | 1 | 2015 | 129 | 0.120 |
Why?
| | Cell Division | 1 | 2016 | 758 | 0.120 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 154 | 0.120 |
Why?
| | Stromal Cells | 1 | 2014 | 96 | 0.120 |
Why?
| | Melanoma | 1 | 2020 | 619 | 0.120 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 385 | 0.120 |
Why?
| | Cytokines | 2 | 2019 | 1840 | 0.120 |
Why?
| | Sarcoma | 1 | 2015 | 137 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 384 | 0.110 |
Why?
| | Cell Line | 2 | 2009 | 2635 | 0.110 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 14 | 0.110 |
Why?
| | Receptor Cross-Talk | 1 | 2013 | 20 | 0.110 |
Why?
| | Gonanes | 1 | 2013 | 27 | 0.110 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 520 | 0.110 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 36 | 0.110 |
Why?
| | ras Proteins | 1 | 2013 | 138 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2015 | 636 | 0.100 |
Why?
| | Pyrimidines | 1 | 2015 | 376 | 0.100 |
Why?
| | Gene Silencing | 1 | 2013 | 171 | 0.100 |
Why?
| | Pyrazoles | 1 | 2015 | 362 | 0.100 |
Why?
| | Thy-1 Antigens | 2 | 2009 | 11 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1518 | 0.100 |
Why?
| | Female | 10 | 2020 | 59446 | 0.100 |
Why?
| | Transcriptome | 1 | 2016 | 724 | 0.090 |
Why?
| | Disease Progression | 1 | 2018 | 2380 | 0.090 |
Why?
| | CD24 Antigen | 1 | 2010 | 20 | 0.090 |
Why?
| | Epithelial-Mesenchymal Transition | 3 | 2019 | 167 | 0.090 |
Why?
| | Mice, Inbred NOD | 2 | 2023 | 555 | 0.090 |
Why?
| | Blotting, Western | 1 | 2013 | 1147 | 0.090 |
Why?
| | Dimethyl Sulfoxide | 1 | 2010 | 43 | 0.090 |
Why?
| | Free Radical Scavengers | 1 | 2010 | 78 | 0.080 |
Why?
| | Alkylating Agents | 1 | 2009 | 27 | 0.080 |
Why?
| | Asbestos | 1 | 2009 | 19 | 0.080 |
Why?
| | Computational Biology | 1 | 2013 | 530 | 0.080 |
Why?
| | Mutagenesis | 1 | 2010 | 168 | 0.080 |
Why?
| | Gamma Rays | 1 | 2009 | 48 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 961 | 0.080 |
Why?
| | Cell Hypoxia | 1 | 2010 | 220 | 0.080 |
Why?
| | Clone Cells | 1 | 2009 | 247 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2015 | 615 | 0.080 |
Why?
| | Apoptosis | 4 | 2019 | 2362 | 0.080 |
Why?
| | Rabbits | 1 | 2010 | 733 | 0.080 |
Why?
| | Keratinocytes | 2 | 2022 | 216 | 0.080 |
Why?
| | Cell Cycle Proteins | 3 | 2020 | 551 | 0.080 |
Why?
| | Glycosylphosphatidylinositols | 1 | 2007 | 9 | 0.070 |
Why?
| | Transfection | 1 | 2009 | 866 | 0.070 |
Why?
| | Cell Survival | 1 | 2010 | 1020 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2013 | 756 | 0.070 |
Why?
| | Genetic Markers | 1 | 2007 | 320 | 0.070 |
Why?
| | Maximum Tolerated Dose | 2 | 2015 | 183 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2177 | 0.060 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1167 | 0.060 |
Why?
| | RNA Interference | 2 | 2016 | 433 | 0.050 |
Why?
| | Time Factors | 2 | 2010 | 6112 | 0.050 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2022 | 63 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 193 | 0.050 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2020 | 23 | 0.050 |
Why?
| | Feedback, Physiological | 1 | 2020 | 68 | 0.040 |
Why?
| | Prognosis | 2 | 2019 | 3327 | 0.040 |
Why?
| | Biomarkers | 2 | 2019 | 3405 | 0.040 |
Why?
| | Heat-Shock Proteins | 1 | 2019 | 113 | 0.040 |
Why?
| | Hyaluronic Acid | 1 | 2020 | 188 | 0.040 |
Why?
| | Molecular Chaperones | 1 | 2019 | 157 | 0.040 |
Why?
| | Transplantation, Heterologous | 1 | 2018 | 181 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2019 | 309 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 367 | 0.040 |
Why?
| | Male | 6 | 2020 | 55534 | 0.040 |
Why?
| | Monocytes | 1 | 2020 | 502 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 442 | 0.040 |
Why?
| | Tumor Stem Cell Assay | 1 | 2016 | 33 | 0.040 |
Why?
| | Gene Expression | 2 | 2015 | 1421 | 0.030 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 41 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 259 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 299 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 22 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.030 |
Why?
| | Lamin Type A | 1 | 2015 | 40 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1644 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 62 | 0.030 |
Why?
| | Phosphorylation | 1 | 2019 | 1569 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 590 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 21 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 36 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2016 | 535 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 620 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 347 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 206 | 0.030 |
Why?
| | Side-Population Cells | 1 | 2013 | 9 | 0.030 |
Why?
| | alpha Catenin | 1 | 2013 | 13 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 243 | 0.030 |
Why?
| | Cell Dedifferentiation | 1 | 2013 | 28 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 351 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2015 | 522 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 76 | 0.030 |
Why?
| | Sequence Deletion | 1 | 2013 | 167 | 0.030 |
Why?
| | Middle Aged | 3 | 2019 | 26705 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 228 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2018 | 2565 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2015 | 9084 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 728 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 293 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 807 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1371 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 1842 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4411 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 750 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2015 | 1018 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2015 | 1262 | 0.020 |
Why?
| | Aged | 2 | 2019 | 19056 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1947 | 0.020 |
Why?
| | Fusion Regulatory Protein-1 | 1 | 2007 | 1 | 0.020 |
Why?
| | Tetraspanin 24 | 1 | 2007 | 5 | 0.020 |
Why?
| | Hybrid Cells | 1 | 2007 | 49 | 0.020 |
Why?
| | MicroRNAs | 1 | 2013 | 600 | 0.020 |
Why?
| | Mitomycin | 1 | 2006 | 27 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1527 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2006 | 72 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2279 | 0.020 |
Why?
| | Cross-Linking Reagents | 1 | 2006 | 181 | 0.020 |
Why?
| | Organometallic Compounds | 1 | 2006 | 98 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 993 | 0.010 |
Why?
| | Adult | 2 | 2015 | 30514 | 0.010 |
Why?
| | Young Adult | 1 | 2014 | 10452 | 0.010 |
Why?
|
|
Keysar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|